BPMX is setting up to be the next large biotech runner from the 40c area. Global partner news could come at any time per its last earnings report. “ Locust Walk has now initiated efforts to secure a global strategic development and commercialization partner for BioPharmX’s late-stage topical minocycline drug candidates.” $5.3m is a ridiculously...